Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Hantop Inc. is a prominent player within the manufacturing sector, primarily engaged in producing high-quality precision machine tools. These include CNC (Computer Numerical Control) systems, crucial for automating tooling operations in various industries. Serving sectors such as automotive, aerospace, and electronics, Hantop's products facilitate enhanced productivity and precision in manufacturing processes. The company is well-regarded for its innovation in developing advanced machine tool solutions that meet stringent industry standards, making it a critical component in industrial supply chains. By continually adopting cutting-edge technologies, Hantop Inc. remains a significant contributor to the technological advancement and operational efficiency of its clients, positioning itself effectively in the global manufacturing landscape.
₩374.00
+₩0.00 (+0.00%)
EOD Jul 2, 2026
Operating margin is thin at 4.36%. Limited cushion if revenue slows or costs rise, not the profile of a wide-moat business.
Revenue declined 2.9% YoY. The question is whether this is cyclical or a structural shift.
Net debt of ₩63.57B represents 55.2x FCF, leverage limits flexibility.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
₩81.90B
▼ -2.9% YoY
Net Income (TTM)
-₩1.26B
▲ +138.9% YoY
Op. Margin
2.48%
ROIC
2.88%
▲ +0.4pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
₩659M
▲ +158.6% YoY
Op. Cash Flow (TTM)
₩5.47B
▲ +531.8% YoY
Net Debt
₩63.57B
Cash & Equiv.
₩9.85B
3Y CAGR: -6.0%
Continue Research
Hantop (002680.XKRX) trades above a two-stage DCF intrinsic value of about KRW -1,679.81 per share, so at KRW 374.00 the stock looks overvalued (549.1% above estimated intrinsic value). A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Hantop scores 27/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full methodology. This is analysis, not investment advice.
Intrinsiqq's two-stage DCF estimates an intrinsic value of about KRW -1,679.81 per share for 002680.XKRX, projecting its recent free cash flow forward with a growth rate that fades toward a long-run rate and discounting it back to today. Applying a 25% margin of safety gives a more conservative fair-value entry around KRW -1,259.86. At today's KRW 374.00, that puts the stock about 549.1% above estimated intrinsic value. The result is sensitive to the growth and discount-rate inputs, so it is best to run conservative, base and optimistic cases. You can adjust all of them yourself with the sliders on the DCF tab.
Hantop scores 27 out of 100 on Intrinsiqq's quality score, a weighted blend of 7 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a 2.5% operating margin and a 2.9% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. 002680.XKRX currently trades above its estimated intrinsic value and scores 27/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.